DGAP-News: Neovacs S.A. / Key word(s): Study NEOVACS INITIATES CLINICAL PROGRAM IN DERMATOMYOSITIS 16.06.2015 / 08:00 --------------------------------------------------------------------- PRESS RELEASE NEOVACS INITIATES CLINICAL PROGRAM IN DERMATOMYOSITIS - Extension of IFNα-Kinoid program to include Dermatomyositis - Formation of Clinical Advisory Board - Anticipated trial launch early 2016 Paris and Boston, June 16, 2015 - NEOVACS (Alternext Paris: ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, today announced the launch of its clinical development program in Dermatomyositis (DM), an orphan skin and muscular condition with significant unmet medical need. Neovacs is extending its IFNα-Kinoid clinical program beyond lupus to include adult and pediatric DM - an indication where a positive IFNα signature plays a decisive role[1]. The decision follows a recommendation earlier this year by the Company's Scientific Advisory Board to pursue IFNα-Kinoid as a potential treatment for DM and extensive due diligence in researching IFN-related diseases that could benefit from this treatment modality. Neovacs plans to conduct a multicentric phase I/IIa trial of IFNα-Kinoid in adult DM in 15 patients which is anticipated to launch in early 2016 in France and other European countries. "Dermatomyositis demonstrates a promising therapeutic candidate pipeline expansion, given the demonstrated role of IFNα in this auto-immune disease. As DM is an orphan condition, this is also an opportunity to bring needed relief to thousands of patients, most of them children, for whom there is currently no satisfactory biotherapy," commented Miguel Sieler, CEO of Neovacs. "We believe that the IFNα-Kinoid in DM will be a development driver for Neovacs, with a limited impact on expenditures. Neovacs will apply for grants dedicated to rare diseases to support the funding of the DM program." DM is an inflammatory disease characterized by severe skin lesions and muscle weakness with a variable impact on physical capacities. DM can also affect the vascular, pulmonary, gastrointestinal and cardiac systems. Approximately one third of DM patients will develop cancer within three years[2]. DM affects primarily children, and mostly females. No biological treatment has been registered to date in this indication. With a prevalence between 1 in 50,000 and 1 in 10,000 cases[3], DM is considered an orphan disease both in North America and in Europe. It is estimated that there are currently approximately 87,000 patients[4] with DM in the EU. Because of the recognized orphan status of DM, Neovacs estimates that clinical development of IFNα-Kinoid in this indication could be considerably shortened, with the potential to bring a treatment to patients in a few years. Formation of a Clinical Advisory Board To sustain and support it in this endeavor, Neovacs has formed a cross disciplinary Clinical Advisory Board (CAB) composed of leading experts in DM: - Prof. Olivier Benveniste, M.D., Ph.D., Hôpital Pitié-Salpêtrière, Paris - Prof. Eric Hachulla, M.D., Ph.D., Centre Hospitalier Regional Universitaire de Lille, France - Dr. Jean-David Bouaziz, M.D.,Ph.D., Hôpital Saint-Louis, Paris - Prof. Werner Stenzel, M.D. ,Ph.D., Charité Universitätmedizin, Berlin - Prof. Ingrid Lundberg, M.D., Karolinska Universitetssjukhuset, Stockholm These board members will be instrumental not only in bringing their expertise to Neovacs in preparing for and defining the metholodology, target population, and evaluation criteriafor the DM trial; but also in assisting with trial development and patient recruitment. The IFNα-Kinoid program in DM could be initiated as early as 2016. [1] Baechler, ART 2011; Wong, Plos One 2012; Greenberg, Genes immun 2012; Shiba, Rheumatol Int 2014 [2] http://www.orpha.net/consor/cgi-bin/OC_Exp.php?Expert=221 [3] Ibid [4]Estimated population assessed taking into account a 1.7/10,000 prevalence in the European Union, and a total EU population of 511,100,000 (Eurostat 2014). Source: EMA/COMP/660609/2014, 12 January 2015 About Neovacs Created in 1993, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNα-Kinoid, an immunotherapy being developed for the indication of lupus and dermatomyositis. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases. For more information on Neovacs, please visit www.neovacs.fr Contacts NEOVACS - Investor Relations Nathalie Trépo +33 (0)1 53 10 93 00 ntrepo@neovacs.com Investor Relations / Financial Communications - NewCap Valentine Brouchot / Pierre Laurent +33 (0)1 44 71 94 94 neovacs@newcap.fr Investor Relations / Financial Communications Germany - MC Services Raimund Gabriel +49-89-210228-30 raimund.gabriel@mc-services.eu Press / U.S. Inquiries - The Ruth Group Melanie Sollid-Penton 1.646.536.7023 msollid@theruthgroup.com --------------------------------------------------------------------- 16.06.2015 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: Neovacs S.A. 3-5, Impasse Reille 75014 Paris France Phone: +33 (0)1 53 10 93 00 Fax: +33 (0)1 53 10 93 03 E-mail: www.neovacs.fr Internet: info@neovacs.fr ISIN: FR0004032746 WKN: A1CVKR Listed: Regulated Unofficial Market in Stuttgart; Open Market in Frankfurt End of News DGAP News-Service --------------------------------------------------------------------- 368519 16.06.2015
DGAP-News: NEOVACS INITIATES CLINICAL PROGRAM IN
Top 10 Most Recent News Articles
Employment Law Suit Hits ABC: Alleged Wage Violations
ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...
Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit
High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...
Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal
Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...
Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly
Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...
Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake
Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...
Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries
JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...
Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path
New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...
Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments
Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....
Continue Reading
Local Voices to Shape Mekong's Story in New Alliance
Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...
Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win
Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...
Continue ReadingTop 5 Most Recently Viewed Articles
BJ's Wholesale Club Exceeds Expectations with Q4 Earnings
BJ's Wholesale Club Achieves Impressive Q4 Results BJ’s Wholesale Club Holdings, Inc. (NYSE: BJ) has delivered a noteworthy performance in its latest financial results, showcasing resilience and growth in a competitive market. The company's fourth-quarter performance has not only exceeded expectations but also highlighted significant strengths in key operational areas....
Continue Reading
Elemeno Health Appoints Tim Coulter as New CEO for Growth
Elemeno Health Welcomes Tim Coulter as New CEO Elemeno Health, a leader in microlearning solutions for healthcare staff, has made a significant announcement regarding its leadership. The company is thrilled to introduce Tim Coulter as its new Chief Executive Officer. With an impressive track record spanning over two decades in health technology and enterprise software,...
Continue Reading
Emerging Trends and Insights in the Amber Glass Packaging Market
Growth and Innovation in Amber Glass Packaging The global amber glass packaging market has displayed strong resilience and growth potential. Recent studies indicate that this market, valued at USD 8.46 billion, is projected to reach USD 13.15 billion, indicating a robust compound annual growth rate (CAGR). This surge is driven by the multidimensional advantages of amber...
Continue Reading
FiEE, Inc. Celebrates Trading Resumption on Nasdaq as MINM
FiEE, Inc. Announces Trading Resumption on Nasdaq The technology-driven company FiEE, Inc. is excited to share that it will resume trading on the Nasdaq under the existing symbol "MINM". This significant milestone follows a successful hearing with the Nasdaq Hearings Panel, which led to the decision to reinstate trading on the Nasdaq Capital Market. Details of the Trading...
Continue Reading
Vera Therapeutics Expands Talent with Inducement Awards
Vera Therapeutics Expands Talent with Inducement Awards Vera Therapeutics, Inc. (Nasdaq: VERA) has recently taken a significant step towards enhancing its workforce by granting inducement awards. These awards, which were declared by the Compensation Committee on January 8, have been established to attract and retain six new employees. The inducement awards include a...
Continue Reading